Vir Biotechnology, Inc. Proceeds from Stock Options Exercised
Vir Biotechnology, Inc. (VIR) reported Proceeds from Stock Options Exercised of $1.61 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromStockOptionsExercised · last filed 2026-08-05
- Vir Biotechnology, Inc. proceeds from stock options exercised for the quarter ending 2026-06-30 was $1.44M, a 121.88% increase year-over-year.
- Vir Biotechnology, Inc. proceeds from stock options exercised for the quarter ending 2026-03-31 was $174.00K, a 70.90% decline year-over-year.
- Vir Biotechnology, Inc. proceeds from stock options exercised for the quarter ending 2025-12-31 was $1.00K, a 98.88% decline year-over-year.
- Vir Biotechnology, Inc. proceeds from stock options exercised for the quarter ending 2025-09-30 was $101.00K, a 42.25% increase year-over-year.
- Vir Biotechnology, Inc. proceeds from stock options exercised for fiscal 2025 was $1.35M, a 70.76% increase from fiscal 2024.
- Vir Biotechnology, Inc. proceeds from stock options exercised for fiscal 2024 was $790.00K, a 77.32% decline from fiscal 2023.
- Vir Biotechnology, Inc. proceeds from stock options exercised for fiscal 2023 was $3.48M, a 23.16% decline from fiscal 2022.
- Vir Biotechnology, Inc. proceeds from stock options exercised for fiscal 2022 was $4.53M, a 65.33% decline from fiscal 2021.
| Period end | Proceeds from Stock Options Exercised 3 month | Proceeds from Stock Options Exercised 6 month | Proceeds from Stock Options Exercised 9 month | Proceeds from Stock Options Exercised 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.61M 10-Q · filed 2026-08-05 | $1.61M derived: sum of 3 quarters · filed 2026-08-05 | $1.72M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $174.00K 10-Q · filed 2026-05-07 | $175.00K derived: sum of 2 quarters · filed 2026-05-07 | $276.00K derived: sum of 3 quarters · filed 2026-05-07 | $925.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $102.00K derived: sum of 2 quarters · filed 2026-02-23 | $751.00K derived: sum of 3 quarters · filed 2026-08-05 | $1.35M 10-K · filed 2026-02-23 |
| 2025-09-30 | $101.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $750.00K derived: sum of 2 quarters · filed 2026-08-05 | $1.35M 10-Q · filed 2025-11-05 | $1.44M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $649.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.25M 10-Q · filed 2026-08-05 | $1.34M derived: sum of 3 quarters · filed 2026-08-05 | $1.41M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $598.00K 10-Q · filed 2026-05-07 | $687.00K derived: sum of 2 quarters · filed 2026-05-07 | $758.00K derived: sum of 3 quarters · filed 2026-05-07 | $1.17M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $89.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $160.00K derived: sum of 2 quarters · filed 2026-02-23 | $569.00K derived: sum of 3 quarters · filed 2026-02-23 | $790.00K 10-K · filed 2026-02-23 |
| 2024-09-30 | $71.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $480.00K derived: sum of 2 quarters · filed 2025-11-05 | $701.00K 10-Q · filed 2025-11-05 | $790.00K derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | $409.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $630.00K 10-Q · filed 2025-08-06 | $719.00K derived: sum of 3 quarters · filed 2026-02-23 | $1.06M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | $221.00K 10-Q · filed 2025-05-08 | $310.00K derived: sum of 2 quarters · filed 2026-02-23 | $653.00K derived: sum of 3 quarters · filed 2026-02-23 | $1.40M derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | $89.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $432.00K derived: sum of 2 quarters · filed 2026-02-23 | $1.17M derived: sum of 3 quarters · filed 2026-02-23 | $3.48M 10-K · filed 2026-02-23 |
| 2023-09-30 | $343.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $1.08M derived: sum of 2 quarters · filed 2024-11-04 | $3.40M 10-Q · filed 2024-11-04 | $4.33M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $742.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $3.05M 10-Q · filed 2024-08-01 | $3.98M derived: sum of 3 quarters · filed 2025-02-27 | $6.03M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $2.31M 10-Q · filed 2024-05-03 | $3.24M derived: sum of 2 quarters · filed 2025-02-27 | $5.29M derived: sum of 3 quarters · filed 2025-02-27 | $6.36M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $932.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $2.98M derived: sum of 2 quarters · filed 2025-02-27 | $4.05M derived: sum of 3 quarters · filed 2025-02-27 | $4.53M 10-K · filed 2025-02-27 |
| 2022-09-30 | $2.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $3.12M derived: sum of 2 quarters · filed 2023-11-03 | $3.60M 10-Q · filed 2023-11-03 | $7.04M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | $1.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $1.56M 10-Q · filed 2023-08-04 | $5.00M derived: sum of 3 quarters · filed 2024-02-26 | $8.69M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | $484.00K 10-Q · filed 2023-05-08 | $3.93M derived: sum of 2 quarters · filed 2024-02-26 | $7.62M derived: sum of 3 quarters · filed 2024-02-26 | $11.21M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | $3.44M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $7.13M derived: sum of 2 quarters · filed 2024-02-26 | $10.72M derived: sum of 3 quarters · filed 2024-02-26 | $13.08M 10-K · filed 2024-02-26 |
| 2021-09-30 | $3.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $7.28M derived: sum of 2 quarters · filed 2022-11-03 | $9.63M 10-Q · filed 2022-11-03 | $10.15M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $3.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $5.95M 10-Q · filed 2022-08-09 | $6.46M derived: sum of 3 quarters · filed 2023-02-28 | $7.62M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $2.35M 10-Q · filed 2022-05-05 | $2.87M derived: sum of 2 quarters · filed 2023-02-28 | $4.02M derived: sum of 3 quarters · filed 2023-02-28 | $6.27M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $519.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $1.67M derived: sum of 2 quarters · filed 2023-02-28 | $3.92M derived: sum of 3 quarters · filed 2023-02-28 | $4.06M 10-K · filed 2023-02-28 |
| 2020-09-30 | $1.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $3.40M derived: sum of 2 quarters · filed 2021-11-04 | $3.54M 10-Q · filed 2021-11-04 | $3.60M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $2.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $2.39M 10-Q · filed 2021-08-05 | $2.45M derived: sum of 3 quarters · filed 2022-02-28 | $2.81M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $143.00K 10-Q · filed 2021-05-06 | $206.00K derived: sum of 2 quarters · filed 2022-02-28 | $570.00K derived: sum of 3 quarters · filed 2022-02-28 | $1.21M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $63.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $427.00K derived: sum of 2 quarters · filed 2022-02-28 | $1.06M derived: sum of 3 quarters · filed 2022-02-28 | $1.13M 10-K · filed 2022-02-28 |
| 2019-09-30 | $364.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $999.00K derived: sum of 2 quarters · filed 2020-11-10 | $1.07M 10-Q · filed 2020-11-10 | $1.32M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $635.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | $702.00K 10-Q · filed 2020-08-11 | $961.00K derived: sum of 3 quarters · filed 2021-02-25 | |
| 2019-03-31 | $67.00K 10-Q · filed 2020-05-12 | $326.00K derived: sum of 2 quarters · filed 2021-02-25 | ||
| 2018-12-31 | $259.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $584.00K 10-K · filed 2021-02-25 | ||
| 2018-09-30 | $325.00K 10-Q · filed 2019-11-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |